Per-cycle, PLD cost $2509, bevacizumab cost $7585, and pembrolizumab cost $9026.
p53 mutational status may be a viable strategy upon which to base the course of therapy.
Researchers randomly assigned 74 patients to receive everolimus plus letrozole daily or tamoxifen daily plus medroxyprogesterone daily on alternating weeks.
A study concluded that adjuvant therapy with a taxane and a platinum agent was not superior over standard therapy for women with high-risk endometrial cancer.
A subset of patients with advanced endometrial cancer experienced durable partial responses to pembrolizumab.
Study data suggest that SLN mapping is more cost-effective and more efficacious than routine LND or selective LND.
Study results suggest that aggressive molecular subtypes of endometrial cancer are more common among the African American population.
Patients with endometrial cancer who have isolated tumor cells identified by sentinel lymph node mapping should not routinely receive adjuvant chemotherapy.
Weight loss during menopause is associated with a lower risk of endometrial cancer.
Sentinel lymph node mapping with indocyanine green accurately diagnoses metastatic disease in patients with endometrial cancer.
For young patients with endometrial cancer, survival does not appear to be significantly impacted by hormone therapy (HT) to preserve fertility.
In women, the association between obesity and endometrial cancer is stronger than in any other type of cancer.
This article reviews the current evidence for the role of aromatase inhibitors (AIs) in the treatment of advanced stage or recurrent endometrial cancer.
Treatment with selinexor is active in patients with heavily pretreated patients with metastatic ovarian or endometrial cancer.
Researchers argue that combination therapies targeting both mutations in the PI3K pathway and HER2 or hormone receptor overexpression should be evaluated across cancer types.
Patients with mismatch repair deficiency cancers may receive durable clinical benefit with pembrolizumab.
Limiting Lynch syndrome (LS) testing to women younger than 60 years could result in missing a significant number of genetic disease.
The incidence of endometrial cancers is elevated for women across all racial/ethnic groups, while non-Hispanic black women have excess incidence.
Use of oral contraceptives confers long-term protection against endometrial cancer.
ASCO's endorsement of the ASTRO guidelines for adjuvant radiotherapy for endometrial cancer provides additional guidance for clinicians.
Robotic surgery is safe and feasible for the surgical management of morbidly obese patients with endometrial cancer.
Ridaforolimus demonstrates activity in advanced endometrial cancer but is associated with significant toxicity.
Adhering to a Mediterranean diet may significantly reduce a woman's risk of endometrial cancer.
Second-line dovitinib in FGFR2-mutated and FGFR2-non-mutated advanced or metastatic endometrial cancer had single-agent activity.
Oral bisphosphonates may greatly reduce the risk of endometrial cancer.
High versus low intake of coffee is associated with a reduced risk for endometrial cancer.
Soy food/isoflavone intake is not associated with endometrial cancer risk in Japanese women.
Patients with endometriod histology and CTNNB1 mutations responded well to everolimus and letrozole.
Nitrogen-containing bisphosphonates associated with reduced risk of endometrial cancer.
Compared to patients who were treated with surgery alone, radiotherapy didn't increase risk for second cancers in pelvic cancers.
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|
|Renal Cell Carcinoma||Regimens||Drugs|
Cancer Therapy Advisor Articles
- CAR-T Trial for Triple-Negative Breast Cancer Under Way
- Daratumumab Combination: New Standard of Care in Transplant-Ineligible Multiple Myeloma
- Adjuvant Trastuzumab Emtansine Confers Improved Outcome in KATHERINE Trial
- Phase 3 GEICAM/CIBOMA Results: Adjuvant Capecitabine in Triple-Negative Breast Cancer
- Extension of Adjuvant Anastrozole Regimen to 10 Years Yields Higher DFS, but Not OS
- Selinexor Trials Move Nuclear Suppressor Protein-Export Inhibition Closer to the Clinic for Multiple Myeloma
- Younger Breast Cancer Patients at Higher Risk for Osteoporosis
- Molecular Mechanisms Underlying Immunosurveillance in Multiple Myeloma Identified
- Gly101Val Mutation Directly Causes Resistance to Venetoclax
- Can Treatments for Childhood ALL Alter the Gut Microbiome?